SLGT2 inhibitors are associated with less development of lung lesions

(MedPage Today) – Chicago – Use of an SGLT2 inhibitor was associated with reduced progression of lung adenocarcinoma in situ, an observational study showed. Nodule growth during an average of 28 months of follow-up was 62% less likely among adults who were prescribed…